BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20633739)

  • 1. Guideline-concordant antidepressant use among patients with major depressive disorder.
    Chen SY; Hansen RA; Gaynes BN; Farley JF; Morrissey JP; Maciejewski ML
    Gen Hosp Psychiatry; 2010; 32(4):360-7. PubMed ID: 20633739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship of guideline-concordant depression treatment and patient adherence to oral diabetes medications.
    Nau DP; Chao J; Aikens JE
    Res Social Adm Pharm; 2005 Sep; 1(3):378-88. PubMed ID: 17138485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up visits by provider specialty for patients with major depressive disorder initiating antidepressant treatment.
    Chen SY; Hansen RA; Farley JF; Gaynes BN; Morrissey JP; Maciejewski ML
    Psychiatr Serv; 2010 Jan; 61(1):81-5. PubMed ID: 20044424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression.
    Trivedi MH; Lin EH; Katon WJ
    CNS Spectr; 2007 Aug; 12(8 Suppl 13):1-27. PubMed ID: 17986951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National trends in psychotropic medication polypharmacy in office-based psychiatry.
    Mojtabai R; Olfson M
    Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of antidepressant medication adherence with employee disability absences.
    Burton WN; Chen CY; Conti DJ; Schultz AB; Edington DW
    Am J Manag Care; 2007 Feb; 13(2):105-12. PubMed ID: 17286530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Working with reactant patients: are we prescribing nonadherence?
    Madsen JW; McQuaid JR; Craighead WE
    Depress Anxiety; 2009; 26(2):129-34. PubMed ID: 18972363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to continuation and maintenance antidepressant use in recurrent depression.
    ten Doesschate MC; Bockting CL; Schene AH
    J Affect Disord; 2009 May; 115(1-2):167-70. PubMed ID: 18760488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder.
    Liu X; Tepper PG; Able SL
    Int Clin Psychopharmacol; 2011 May; 26(3):173-80. PubMed ID: 21278576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving depression care in a psychiatry resident psychopharmacology clinic: measurement, monitoring, feedback and education.
    Shiner B; Green RL; Homa K; Watts BV; Groft A; Torrey WC; Oxman TE
    Qual Saf Health Care; 2010 Jun; 19(3):234-8. PubMed ID: 20457732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of care setting on evidence-based depression treatment for veterans with COPD and comorbid depression.
    Jordan N; Lee TA; Valenstein M; Weiss KB
    J Gen Intern Med; 2007 Oct; 22(10):1447-52. PubMed ID: 17687614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outpatient follow-up for patients with rheumatoid arthritis in relation to New Zealand Rheumatology Association guidelines at Dunedin Hospital.
    Chan G; Goh F; Hodgson T; Hsu E; Johnstone D; Ly J; Platt T; Rodrigues E; Tsai W; Hider P; Gray A; Highton J
    N Z Med J; 2008 May; 121(1274):34-41. PubMed ID: 18535644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders.
    Lee MS; Lee HY; Kang SG; Yang J; Ahn H; Rhee M; Ko YH; Joe SH; Jung IK; Kim SH
    J Affect Disord; 2010 Jun; 123(1-3):216-21. PubMed ID: 19914719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication use patterns and two-year outcome in first-admission patients with major depressive disorder with psychotic features.
    Craig TJ; Grossman S; Bromet EJ; Fochtmann LJ; Carlson GA
    Compr Psychiatry; 2007; 48(6):497-503. PubMed ID: 17954133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How do Argentinean psychiatrists treat depression?].
    Leiderman EA; Nemirovsky M; Elenitza I; Jufe G; Levin S; Mazaira S; Mussa A; Wikinski S
    Vertex; 2007; 18(75):335-43. PubMed ID: 18273418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orosomucoid influences the response to antidepressants in major depressive disorder.
    Harley J; Roberts R; Joyce P; Mulder R; Luty S; Frampton C; Kennedy M
    J Psychopharmacol; 2010 Apr; 24(4):531-5. PubMed ID: 19395425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does adherence to the guideline recommendation for active treatments improve the quality of care for patients with acute low back pain delivered by physical therapists?
    Fritz JM; Cleland JA; Brennan GP
    Med Care; 2007 Oct; 45(10):973-80. PubMed ID: 17890995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inadequate follow-up care for depression and its impact on antidepressant treatment duration among veterans with and without diabetes mellitus in the Veterans Health Administration.
    Jones LE; Turvey C; Carney-Doebbeling C
    Gen Hosp Psychiatry; 2006; 28(6):465-74. PubMed ID: 17088161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.